NeurologicalDisorders

Sage Therapeutics Receives $469 Million Takeover Bid from Biogen: A Game Changer in Neurological Treatments?

1 day ago

In a significant development for the pharmaceutical sector, Sage Therapeutics, a leader in the field of brain health, has attracted attention with a substantial takeover offer from Biogen totaling $469 million. This unexpected bid marks a pivotal moment for Sage, known for its innovative approaches to treating neurological disorders. The proposal comes as both companies strive to enhance their portfolios and capabilities in the competitive biopharmaceutical market.

New Advisory for GSK and Pfizer's RSV Vaccines Due to Rare Neurological Disorder Risks

7 days ago

In a newly released advisory, health authorities have notified clinicians and the public about a potential risk associated with the respiratory syncytial virus (RSV) vaccines developed by GSK and Pfizer. These vaccines, which have been hailed as significant advancements in the fight against RSV, are now under scrutiny due to reports revealing a rare neurological disorder potentially linked to their use.